Advertisement

Topics

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015

07:44 EDT 11 Aug 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-29. This 168-page report is available in PDF from $2000.

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and…

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview 9
Therapeutics Development 10
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Overview 10
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis 11
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Development by Companies 12
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Development by Companies 18
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Companies Involved in Therapeutics Development 20
Altor BioScience Corporation 20
Amgen Inc. 21
Astellas Pharma Inc. 22
AstraZeneca Plc 23
ATLAB Pharma SAS 24
BIND Therapeutics, Inc. 25
Boehringer Ingelheim GmbH 26
Boston Biomedical, Inc. 27
Eli Lilly and Company 28
Exelixis, Inc. 29
Incyte Corporation 30
Johnson & Johnson 31
Merck & Co., Inc. 32
Mirati Therapeutics Inc. 33
Novartis AG 34
Pfizer Inc. 35
Sanofi 36
Sumitomo Dainippon Pharma Co., Ltd. 37
Teva Pharmaceutical Industries Limited 38
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
AdIL-24 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ALT-801 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AMG-228 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
amrubicin hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ATL-101 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AZD-4547 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
B-701 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BBI-503 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
buparlisib hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cabazitaxel - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
cabozantinib s-malate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CEP-11981 - Drug Profile 72
Product Description 72
Mechanism of…

For more information open Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015.

SKU: GMDHC6814IDB

Original Article: Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...